---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070286"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T18:57:46.476964+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kyverna completes SPS Phase 2 enrollment; BLA filing now 1H 2026; Q1 net loss $44.6M

## Summary
- Enrollment completed in KYSA-8 pivotal Phase 2 trial of KYV-101 in stiff person syndrome; topline data 1H 2026.
- BLA filing for KYV-101 in SPS accelerated to 1H 2026 (from prior 2026 guidance).
- FDA aligns on registrational Phase 3 for myasthenia gravis; interim Phase 2 data expected 2H 2025.
- Cash and equivalents $242.6M; runway into 2027 supports first BLA, Phase 3 MG, and pre-launch activities.
- Workforce reduced ~16% in Q1 2025; Q1 net loss $44.6M ($1.03/shr) vs $26.7M ($1.12/shr) in Q1 2024.

## SEC filing metadata
- accession: 0000950170-25-070286
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000095017025070286/0000950170-25-070286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000095017025070286/kytx-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070286
- JSON: https://secwatch.observer/filing/0000950170-25-070286.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.